Skip to content

SS创新国际

US · SSII #3689 按市值排名
2.53 -0.05 -1.94%
实时 - 追踪5344个代码 - 心跳于486秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 10.26 低于历史水平 第2百分位
5年平均 45.40 · 在Medical Devices中排名第109/125
市盈率 -45.67 高于历史水平 第67百分位
5年平均 -63.87 · 前瞻 -45.67
市销率 10.46 低于历史水平 第2百分位
5年平均 52.06 · 前瞻 8.13 · 在Medical Devices中排名第113/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
SS创新国际 (SSII) 507.24M -42.17 9.51 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值3.60 经济护城河None 不确定性Very High

当前股价低于晨星合理价值估算42.2%。

合理价值

While SS Innovations International Inc may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 24% discount to our quantitative fair value estimate of $3.60 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's solid growth bolsters our fair value estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 122.9% falls in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.

Conversely, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 237.4, for example, ranks in the top 10% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

经济护城河

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

SS创新国际 讨论区 0 条评论

发表评论